Blake Borgeson - Jan 24, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Jan 24, 2023
Transactions value $
-$77,368
Form type
4
Date filed
1/26/2023, 05:04 PM
Previous filing
Jan 12, 2023
Next filing
Feb 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale -$77.4K -8.89K -0.12% $8.71 7.61M Jan 24, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.49 to $8.87 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.